Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Composition for Treating Uterine Fibroid (SB-UF)

NCT: NCT04762316 · COMPLETED

NCT IDNCT04762316
StatusCOMPLETED
Start Date2019-01-01
Completion2021-02-01

Brief Summary

Pregnenolone \& Pyridoxal Phosphate SB-UF for treating uterine fibroids in women's pregnancies to lose the size of fibroids and to dissolve fibroids. Uterine fibroids are a very common finding in women pregnancy of reproductive age, fibroids fast grow in the first trimester of pregnancy. SB-UF against the rapid growth of fibroids under the influence of hormones during pregnancy. Use SB-UF to think about regulating stable Oestrogen levels and dissolving fibroids. This is a substantial insight into disease pathogenesis, with a clear path toward clinical application, which would lead to a substantial advance and perfection in management or public health policy.

Frequently Asked Questions

What is Composition for Treating Uterine Fibroid (SB-UF)?

Composition for Treating Uterine Fibroid (SB-UF) is a clinical trial registered under NCT04762316. Current status: COMPLETED.

What is the status of NCT04762316?

The current status of NCT04762316 (Composition for Treating Uterine Fibroid (SB-UF)) is: COMPLETED.

When did Composition for Treating Uterine Fibroid (SB-UF) start?

Composition for Treating Uterine Fibroid (SB-UF) started on 2019-01-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.